Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F19%3A10391192" target="_blank" >RIV/00064165:_____/19:10391192 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/19:10391192 RIV/00216208:11120/19:43917727 RIV/00216208:11150/19:10391192 RIV/65269705:_____/19:00070828 and 3 more
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=5UGUT6jQGl" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=5UGUT6jQGl</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.leukres.2019.02.002" target="_blank" >10.1016/j.leukres.2019.02.002</a>
Alternative languages
Result language
angličtina
Original language name
Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab
Original language description
Chemoimmunotherapy with bendamustine and rituximab is an alternative treatment for elderly patients with CLL. The aim of this observational multicenter study was to prospectively assess efficacy and safety of bendamustine and rituximab in front-line therapy in patients with CLL and significant comorbidities in real hematological practice. Eighty-three consecutive patients with cumulative illness rating scale (CIRS) >6 who received at least one cycle of BR as first-line treatment were included in the study. The median age was 71 years (range, 53-83), the median CIRS was 8 (range, 7-17), and 60.2% of patients had a creatinine clearance <=70 mL/min. FISH analysis, available for 78 cases, showed a del(17p) in 11.5% and del(11q) in 20.5% of patients. Overall response rate was 88.0% with a complete response rate of 20.5%. With median follow-up time of 22 months, the estimated median progression free survival was 35.9 months. Progression free survival and overall survival rates at 2 years were 69.9% and 96.2%, respectively. Grade 3 or 4 neutropenia, thrombocytopenia, and anemia were documented in 40 (48.2%), 14 (16.9%), and 8 (9.6%) patients, respectively. Grade 3 or 4 infections occurred in 14.5% of patients. Chemoimmunotherapy with BR is an effective therapeutic option with manageable toxicity for the initial treatment of CLL patients with significant comorbidities. ClinicalTrials.gov Identifier: NCT02381899.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
<a href="/en/project/NV15-30015A" target="_blank" >NV15-30015A: Analysis of clonal heterogeneity in chronic lymphocytic leukemia using next generation sequencing of B cell receptor. A national study.</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Leukemia Research
ISSN
0145-2126
e-ISSN
—
Volume of the periodical
79
Issue of the periodical within the volume
April
Country of publishing house
GB - UNITED KINGDOM
Number of pages
5
Pages from-to
17-21
UT code for WoS article
000460898400004
EID of the result in the Scopus database
2-s2.0-85061711068